As part of the Cancer Drugs Fund (CDF) transitional arrangements, NICE committed to conducting a Single Technology Appraisal of Nelarabine for treating refractory T-cell lymphoblastic non-Hodgkin’s lymphoma [ID1044]. As such, a formal referral of this topic was received in June 2016.
NICE have discussed the current suitability of this topic for the technology appraisal work programme with NHS England, now that further information has become available during the early scoping process of the appraisal. Nelarabine has a significant off label use in clinical practice, especially in the paediatric and young adult setting (whilst nelarabine is licensed as a single agent its standard use is in combination with other agents). In view of this, as well as the fact that the patent for the technology is shortly due to expire, NICE and NHS England regards that a commissioning decision would be best taken by the CDF ‘off label process’ feeding into the NHS England Specialised Commissioning Policy Development prioritisation process. As a consequence, the NICE STA will be discontinued. CDF transition funding will remain in place until a commissioning decision is taken by the CDF ‘off label process’.
| Status | Discontinued |
| Decision | Selected |
| Process | TA |
| ID number | 1044 |
Project Team
| Project lead | Michelle Adhemar |
Email enquiries
- If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 27 December 2017 | Expected publication |
| 01 December 2016 | Discontinued. As part of the Cancer Drugs Fund (CDF) transitional arrangements, NICE committed to conducting a Single Technology Appraisal of Nelarabine for treating refractory T-cell lymphoblastic non-Hodgkin’s lymphoma [ID1044]. As such, a formal referral of this topic was received in June 2016. NICE have discussed the current suitability of this topic for the technology appraisal work programme with NHS England, now that further information has become available during the early scoping process of the appraisal. Nelarabine has a significant off label use in clinical practice, especially in the paediatric and young adult setting (whilst nelarabine is licensed as a single agent its standard use is in combination with other agents). In view of this, as well as the fact that the patent for the technology is shortly due to expire, NICE and NHS England regards that a commissioning decision would be best taken by the CDF ‘off label process’ feeding into the NHS England Specialised Commissioning Policy Development prioritisation process. As a consequence, the NICE STA will be discontinued. CDF transition funding will remain in place until a commissioning decision is taken by the CDF ‘off label process’. |
| 08 June 2016 | Referral |
For further information on our processes and methods, please see our CHTE processes and methods manual